Filamin-A regulates actin-dependent clustering of HIV receptors

Autor: Alfonso Valencia, Antonella Viola, Santos Mañes, Dimiter S. Dimitrov, Lorena Martínez-Prats, Rosa Ana Lacalle, Concepción Gómez-Moutón, Sonia Jiménez-Baranda, Ana M. Rojas, Carlos Martínez-A, Emilia Mira, Rafael Delgado
Přispěvatelé: Ministerio de Educación y Ciencia (España), Consejo Superior de Investigaciones Científicas (España), European Commission, Instituto de Salud Carlos III, National Cancer Institute (US), Pfizer
Jazyk: angličtina
Rok vydání: 2007
Předmět:
Zdroj: Digital.CSIC. Repositorio Institucional del CSIC
instname
Popis: Human immunodeficiency virus (HIV)-1 infection requires envelope (Env) glycoprotein gp120-induced clustering of CD4 and coreceptors (CCR5 or CXCR4) on the cell surface; this enables Env gp41 activation and formation of a complex that mediates fusion between Env-containing and target-cell membranes1. Kinetic studies show that viral receptors are actively transported to the Env-receptor interface in a process that depends on plasma membrane composition and the actin cytoskeleton2, 3, 4, 5, 6, 7. The mechanisms by which HIV-1 induces F-actin rearrangement in the target cell remain largely unknown. Here, we show that CD4 and the coreceptors interact with the actin-binding protein filamin-A, whose binding to HIV-1 receptors regulates their clustering on the cell surface. We found that gp120 binding to cell receptors induces transient cofilin-phosphorylation inactivation through a RhoA–ROCK-dependent mechanism. Blockade of filamin-A interaction with CD4 and/or coreceptors inhibits gp120-induced RhoA activation and cofilin inactivation. Our results thus identify filamin-A as an adaptor protein that links HIV-1 receptors to the actin cytoskeleton remodelling machinery, which may facilitate virus infection.
This work was supported in part by the Spanish Ministry of Education and Science (SAF2005-00241) and the Intramural CSIC Program (PIF 20050F0212) to S.M., the European Union FP6 (INNOCHEM, LSHB-CT-2005-518167) to S.M. and C.M.A., the Instituto de Salud Carlos III (FIS030300; G030173) to R.D., and the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research to D.S.D. A.R. is a recipient of MIRG-CT-2005-016499. The Department of Immunology and Oncology was founded and is supported by the Spanish National Research Council (CSIC) and by Pfizer.
Databáze: OpenAIRE